Ewing Sarcoma

P=N/A, N=300, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

These findings highlight an unexpected tumor-suppressive role for cIAP1 in fusion-driven sarcomas, contrasting with its pro-survival function in other cancers. Collectively, our results identify cIAP1 as a prognostically relevant, EWSR1::FLI1-regulated hub whose re-expression disrupts tumor progression, offering a potential therapeutic strategy to restore tumor-suppressive pathways in EwS.

Neoadjuvant chemotherapy can facilitate tumor conversion, while surgery plays a pivotal role in localized cases with incomplete chemotherapeutic response. Multidisciplinary management is essential for optimizing outcomes.

P2, N=33, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

P1, N=50, Recruiting, Amgen | Not yet recruiting --> Recruiting

However, these features may not correlate with prognosis. This study represents the first systematic radiologic evaluation of NFATC2-rearranged bone sarcomas, highlighting distinctive characteristics that may aid pathologists in their initial diagnostic assessments.

Anti-PD-1/PD-L1-based ICI strategies have not led to significant improvements in outcomes for ovarian cancer. Future studies should focus on optimizing biomarker selection, evaluating combination therapies, and targeting the tumor microenvironment to enhance the efficacy of immunotherapy.

The identification of NSE and S100 as robust prognostic biomarkers suggests that these widely available immunohistochemical stains provide valuable information beyond standard diagnostic information. These findings support the integration of automated data extraction tools in research workflows and suggest that NSE and S100 status should be considered in the design of future risk-stratified clinical trials for Ewing sarcoma.

These results demonstrate that the engineered polyQ fusions entrap endogenous EWS::FLI1 protein into aggregates and reduce its soluble fraction in Ewing sarcoma cells. This study provides an alternative potential for treating Ewing sarcoma and other tumors by directly targeting the oncogenic proteins in the future.

AI-optimized sgRNA prediction accuracy reaches 89.3%. This CC0-licensed architecture defines a new standard for integrated, spatiotemporally programmable precision oncology and is suitable for compassionate-use-ready translational deployment.

As primary treatment is chemotherapy, accurate diagnosis on limited material such as FNAC is critical. The recognition of cytological features and follow up with appropriate ancillary testing has the potential to improve management of these patients.